spironolactone has been researched along with Urinary Bladder Neoplasms in 2 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone was identified as a potent NER inhibitor." | 5.72 | A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. ( Attwood, K; Cao, Q; Chatta, G; Goodrich, DW; Guru, KA; Katsuta, E; Li, QJ; Smith, GJ; Takabe, K; Wang, J; Wang, L; Wei, L; Wu, Y; Xu, B; Xu, D, 2022) |
| "Spironolactone was identified as a potent NER inhibitor." | 1.72 | A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. ( Attwood, K; Cao, Q; Chatta, G; Goodrich, DW; Guru, KA; Katsuta, E; Li, QJ; Smith, GJ; Takabe, K; Wang, J; Wang, L; Wei, L; Wu, Y; Xu, B; Xu, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, D | 1 |
| Cao, Q | 1 |
| Wang, L | 1 |
| Wang, J | 1 |
| Xu, B | 1 |
| Attwood, K | 1 |
| Wei, L | 1 |
| Wu, Y | 1 |
| Smith, GJ | 1 |
| Katsuta, E | 1 |
| Takabe, K | 1 |
| Chatta, G | 1 |
| Guru, KA | 1 |
| Goodrich, DW | 1 |
| Li, QJ | 1 |
| Chuang, YW | 1 |
| Yu, MC | 1 |
| Huang, ST | 1 |
| Yang, CK | 1 |
| Chen, CH | 1 |
| Lo, YC | 1 |
| Lin, CL | 1 |
| Shu, KH | 1 |
| Yu, TM | 1 |
| Kao, CH | 1 |
2 other studies available for spironolactone and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer.
Topics: Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; | 2022 |
Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2017 |